Effect of the synthetic retinoid fenretinide on circulating free prostate-specific antigen, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer.
Effect of the synthetic retinoid fenretinide on circulating free prostate-specific antigen, insulin-like growth factor-I, and insulin-like growth factor binding protein-3 levels in men with superficial bladder cancer.
复制标题
合成类视黄醇芬维A胺对浅表性膀胱癌男性循环游离前列腺特异性抗原、胰岛素样生长因子-I 和胰岛素样生长因子结合蛋白-3 水平的影响。
DOI：
10.1158/1078-0432.ccr-04-1549
复制
发表时间：
2005
期刊：
影响因子：
--
通讯作者：
Decensi,Andrea
中科院分区：
文献类型：
--
作者：
Serrano,Davide;Baglietto,Laura;Johansson,Harriet;Mariette,Frederique;Torrisi,Rosalba;Onetto,Marina;Paganuzzi,Michela;Decensi,Andrea
目的：芬维甲酸(Fenretinide，4-HPR)是一种人工合成的维甲酸，在前列腺癌动物模型中显示出预防作用。实验设计：在一项随机的膀胱癌预防试验中，我们检测了24名服用4-HPR的受试者和24名对照受试者治疗1年后总前列腺特异性抗原(PSA)和游离前列腺特异性抗原(FSA)水平的变化及其与胰岛素样生长因子I(IGF-I)和IGFBP-3水平的关系。结果：4-HPR对总PSA和游离部分PSA水平没有显著影响。4-HPR组和对照组游离PSA值和总PSA值变化的中位数百分比分别为7.6%(95%CI，−4.0~6 9.3)和5.1%(95%CI，−2 1.4~5 9.8)和−7.8(95%CI，−18.2~5 2.5)，−12.3(95%CI，−44.6~9.6)。而在60岁以上的患者中，4-HPR治疗后总游离PSA和游离PSA百分比有升高的趋势，与对照组的下降趋势不同(P=0.002和0.052)。年龄与治疗对游离前列腺特异性抗原的交互作用有统计学意义(P=0.001)。吸烟状况也有类似的规律(与游离PSA的交互作用P=0.011)。PSA水平与IGF-I和IGFBP-3水平之间没有相关性。结论：我们得出结论：4-HPR对循环PSA没有显著影响，但在60岁以下和非吸烟者中它显著增加了游离PSA水平。这些效应可能支持前列腺癌预防的活动，但还需要进一步的研究。
Purpose:Fenretinide (4-HPR) is a synthetic retinoid that has shown a preventive activity in prostate cancer animal models.Experimental Design:We measured the changes in total and free prostate-specific antigen (PSA) and its association with insulin-like growth factor I (IGF-I) and IGFBP-3 levels after 1 year of treatment in 24 subjects given 4-HPR and 24 control subjects enrolled in a randomized bladder cancer prevention trial.Results:No significant effect of 4-HPR was observed on total and free fraction of PSA levels. The median percentage [95 confidence interval (95% CI)] change for % free PSA and total PSA in the 4-HPR and the control group were, respectively, 7.6 (95% CI, −4.0 to 69.3) versus 5.1 (95% CI, −21.4 to 59.8) and −7.8 (95% CI, −18.2 to 52.5) versus −12.3 (95% CI, −44.6 to 9.6). However, in patients ages <60 years, there was a trend to an increase of total free PSA and % free PSA after treatment with 4-HPR that was different from a trend to a decrease in the control group (P= 0.002 and 0.052, respectively). The interaction between age and treatment was statistically significant on free PSA (P= 0.001). A similar pattern was noted with smoking status (P= 0.011 for the interaction on free PSA). No association was observed between PSA levels and IGF-I or IGFBP-3 levels.Conclusions:We conclude that 4-HPR has no significant effect on circulating PSA, but it increases significantly free PSA levels in subjects younger than 60 years and in nonsmokers. These effects might support an activity in prostate cancer prevention but further studies are required.